Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
K-285
- Development stage
- Unknown
- Lead developer
- Kowa Research Institute
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
K-285 is an investigational topical gel developed for the treatment of delayed onset muscle soreness (DOMS). It has been evaluated in phase II clinical trials, where its efficacy and safety were compared to menthol gel in subjects experiencing DOMS induced by exercise. The studies involved randomized, double-blind, active comparator designs with endpoints focused on pain reduction and safety assessments. The mechanism of action is not explicitly stated in available sources; however, it is being studied as a topical analgesic for musculoskeletal pain relief.
Beyond the preview
Go deeper on K-285.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on K-285.